Menveo + Bexsero

Menveo + Bexsero is a combination vaccine regimen providing broad protection against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W-135, and Y. Menveo is a quadrivalent conjugate vaccine (MenACWY-CRM) that utilizes capsular polysaccharides from serogroups A, C, W-135, and Y conjugated to a CRM197 carrier protein to enhance immunogenicity through T-cell involvement. Bexsero is a multicomponent vaccine (MenB-4C) targeting serogroup B, containing three recombinant proteins—Neisserial adhesin A (NadA), Neisserial heparin-binding antigen (NHBA), and factor H-binding protein (fHbp)—along with outer membrane vesicles (OMV) containing Porin A (PorA). This combination is being evaluated in clinical trials, such as the MENPI study led by Thomas Benfield, to assess safety and immunogenicity in high-risk populations, including adults living with HIV who are at increased risk for invasive meningococcal and pneumococcal infections.

Brand names

MenveoBexsero

Other names

Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccineMeningococcal ACWY-CRM vaccine and Meningococcal group B vaccine